hai Phix174 gene E Conferences | Meetings | Events | Symposiums | ConferenceSeries

International Conferences

Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

 

Recommended Conferences for Phix174 gene E

Phix174 gene E


As per available reports about 283 open access articles, 1123 conferences, 215 national symposiums are presently dedicated exclusively to PhiX174 gene E and about 373 speakers gave presentations on PhiX174 gene E.

A new strategy to develop an effective vaccine is essential to control food-borne Salmonella entericaserovar Enteritidis infections. Bacterial ghosts (BGs), which are non-living, Gram-negative bacterial cell envelopes, are generated by expulsion of the cytoplasmic contents from bacterial cells through controlled expression using the modified cI857/λ PR/gene E expression system. During our initial studies, we have generated S. Enteritidis ghost using the antibiotic resistance gene containing pJHL99 lysis plasmid carrying the mutated lambda PR37-cI857 repressor and PhiX174 lysis gene E. Temperature induction of the lysis gene cassette at 42°C revealed quantitative killing of S. Enteritidis. In the development of genetically inactivated bacterial vaccines, plasmid retention often requires the antibiotic resistance gene markers, the presence of which can cause the potential biosafety hazards such as the horizontal spread of resistance genes. In order to overcome this issue, the new lysis plasmid was constructed by utilizing the approach of balanced-lethal systems based on auxotrophic gene Aspartate semialdehyde dehydrogenase (asd).

OMICS International 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies  and Publishes 700+ Open access journals Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.

The PhiX174 lysis gene E and λPR37-cI857 temperature-sensitive regulatory system was cloned in the asd gene positive plasmid and this novel approach allowed the production of antibiotic resistance marker free S. Enteritidis ghost. Although the generation of the S. Enteritidis was successful by using the above mentioned approach, but the unwanted leaky expression of lysis gene E occurred in the absence of induction temperature, and the bacterial host cell death during the normal growth condition at 28oC. To avoid leaky expression of the bacterial host-toxic PhiX174 lysis gene E from the λPR promoter, a convergent promoter construct was made in which gene E was placed between a sense λPR promoter and an anti-sense ParaBAD promoter. In the presence of L-arabinose, leaky transcription of lysis gene E at 28oC from the sense λPR promoter was repressed by an anti-sense RNA simultaneously expressed from the ParaBAD promoter. The stringent repression of lysis gene E in the absence of induction temperature resulted into higher concentration of bacteria in culture suspension, and consequently higher and stable production of a S. Enteritidis ghost. The S. Enteritidis ghost produced by above described approaches was characterized using scanning and transmission electron microscopy to visualize the transmembrane tunnel structure and loss of cytoplasmic materials, respectively.

The efficacy of the bacterial ghost as a vaccine candidate was evaluated in a chicken model. The chickens from all immunized groups showed significant increases in plasma IgG and intestinal secretory IgA levels. The lymphocyte proliferation response and CD3+CD4+ and CD3+CD8+T cell subpopulations were also significantly increased in all immunized groups. The data indicate that both humoral and cell-mediated immune responses are robustly stimulated. Based on an examination of the protection efficacy measured by observations of gross lesions in the organs and bacterial recovery, the candidate vaccine can provide efficient protection against virulent challenge

Relevant Conferences:

  1. 10th Vaccines & Vaccination Conference, June 16-18, 2016 Rome, Italy
  2. 13th Vaccines & Vaccination Conference,                                                         November 10-12, 2016 Melbourne, Australia
  3. 2nd Applied Microbiology Conference,                                                             October 31-November 02, 2016 Istanbul, Turkey
  4. 6th Cell & Stem Cells Research Conference,                                                      February 29-March 02, 2016 Philadelphia, USA
  5. 2nd Antibiotics Conference October 03-05, 2016 London, UK
  6. 5th Cancer Therapy Conference, September 28-30, 2015 Atlanta, Georgia, USA
  7. Beneficial Microbes: Food, Pharma, Aqua & Beverages Industry Conference, September 23-25, 2016 Phoenix, USA
  8. 4th Bacteriology and Infectious Diseases Conference,                                        May 16-18, 2016 San Antonio, USA
  9. Allergy Conference, March 29-30, 2016 Valencia, Spain
  10. 4th Immunology Conference, September 28-30, 2015 Houston, Texas, USA
  11. 2nd Infectious Diseases Conference, August 25-27, 2016 Philadelphia, USA
  12. 2nd Influenza Conference, September 12-14, 2016 Berlin, Germany
  13. Infection Prevention and Control Conference, Aug 1-2, 2016 Frankfurt, Germany
  14. 2nd Innate Immunity Conference, July 21-22, 2016 Berlin, Germany
  15. 2nd Parasitology Conference, August 01-03, 2016 Manchester, UK
  16. 2nd Antibodies Conference, July 14-15, 2016 Philadelphia, USA
  17. 2nd Neuroimmunology & Therapeutics Conference,                                        March 31-April 02, 2016 Atlanta, USA
  18. Influenza Vaccines for the World, 6-9 October 2015 Sao Rafael Atlantic Hotel, Albufeira, Algarve, Portugal
  19. The 2015 Vaccine Summit, 13th - 15th October 2015 Cineworld: The O2, Peninsula Square, London
  20. Conference on 3Rs Alternatives and Consistency Testing in Vaccine Lot Release Testing, 16 -18 September 2015 Hotel Zuiderduin, The Netherlands
  21. Meningitis and Septicaemia in Children and Adults, 4th - 5th November 2015 Royal Society of Medicine, London, United Kingdom
  22. Conference on 3Rs Alternatives and Consistency Testing in Vaccine Lot Release Testing, 16 -18 September 2015 Hotel Zuiderduin, The Netherlands
  23. Meningitis and Septicaemia in Children and Adults, 4th - 5th November 2015 Royal Society of Medicine, London, United Kingdom
  24. Meningitis and Septicaemia in Children and Adults, 4th - 5th November 2015 Royal Society of Medicine, London, United Kingdom

Relevant Societies:

  1. Southern African HIV Clinicians Society
  2. ANTIAIDS Foundation
  3. AIDS Action Committee of Massachusetts
  4. Infectious Diseases Society of America (IDSA)
  5. American Society for Microbiology
  6. Ecuadorian Society of Medical Technologists Laboratory (SOTEMELAB)
  7. American Society for Microbiology
  8. Médecins Sans Frontières
  9. American Federation for Medical Research

Relevant Companies:

  1.  Metabolon, Inc.
  2.  Boston Biomedical
  3. Zakłady Chemiczne Permedia S.A.
  4.  Astellas
  5.  Cipla
  6.  GlaxoSmithKline plc.
  7.  Merck & Co.
  8.  Novartis
  9.  Pfizer
  10. Sunpharma
  11.  Vaxgen

This page will be updated regularly.

This page was last updated on November 8, 2024

Conference Series Destinations